Advertisement
Advertisement
Novartis CEO says no decision has been taken on Sandoz
By:
ZURICH (Reuters) - Novartis has not decided what to do with its Sandoz generics unit after announcing a strategic review of the business last year, its chief executive said on Monday.
ZURICH (Reuters) – Novartis has not decided what to do with its Sandoz generics unit after announcing a strategic review of the business last year, its chief executive said on Monday.
“No decision has been taken on Sandoz, we continue to evaluate the options,” Vas Narasimhan said at the J.P. Morgan Healthcare conference. He also said the Swiss drugmaker continued to look for value-creating bolt-on acquisitions.
(Reporting by Silke Koltrowitz; Editing by Michael Shields)
About the Author
Reuterscontributor
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:
Did you find this article useful?
Latest news and analysis
Advertisement